Toyota|$17.75 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.81 (¥4,271)-1.13%▼ (in JPY terms)
SoftBank|$20.60 (¥3,281)-3.95%▼ (in JPY terms)
MUFG|$20.63 (¥3,287)-3.75%▼ (in JPY terms)
Keyence|$455.15 (¥72,510)-1.28%▼ (in JPY terms)
Nintendo|$56.03 (¥8,926)+0.36%▲ (in JPY terms)
NTT|$1.07 (¥170)+0.77%▲ (in JPY terms)
Takeda|$43.51 (¥6,931)-0.09%▼ (in JPY terms)
Tokyo Electron|$54.34 (¥8,657)-1.56%▼ (in JPY terms)
Recruit|$114.21 (¥18,195)+5.02%▲ (in JPY terms)
ITOCHU|$14.65 (¥2,334)-2.59%▼ (in JPY terms)
Honda|$11.28 (¥1,797)-2.10%▼ (in JPY terms)
Shin-Etsu|$34.99 (¥5,574)-0.85%▼ (in JPY terms)
Tokio Marine|$3.67 (¥584)-2.23%▼ (in JPY terms)
Fast Retailing|$529.78 (¥84,400)+0.79%▲ (in JPY terms)
Toyota|$17.75 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.81 (¥4,271)-1.13%▼ (in JPY terms)
SoftBank|$20.60 (¥3,281)-3.95%▼ (in JPY terms)
MUFG|$20.63 (¥3,287)-3.75%▼ (in JPY terms)
Keyence|$455.15 (¥72,510)-1.28%▼ (in JPY terms)
Nintendo|$56.03 (¥8,926)+0.36%▲ (in JPY terms)
NTT|$1.07 (¥170)+0.77%▲ (in JPY terms)
Takeda|$43.51 (¥6,931)-0.09%▼ (in JPY terms)
Tokyo Electron|$54.34 (¥8,657)-1.56%▼ (in JPY terms)
Recruit|$114.21 (¥18,195)+5.02%▲ (in JPY terms)
ITOCHU|$14.65 (¥2,334)-2.59%▼ (in JPY terms)
Honda|$11.28 (¥1,797)-2.10%▼ (in JPY terms)
Shin-Etsu|$34.99 (¥5,574)-0.85%▼ (in JPY terms)
Tokio Marine|$3.67 (¥584)-2.23%▼ (in JPY terms)
Fast Retailing|$529.78 (¥84,400)+0.79%▲ (in JPY terms)

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be installed in Iwata City, Shizuoka Prefecture, and a demonstration experiment will begin in April. Collaboration with the city will be carried out to verify its use in the event of a disaster.”

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be in … 続きを読む

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む